Versão BETA

Acesso livre
Acesso livre

Farmácia / Notícias da Indústria

Estudo de coorte | Em crianças com síndrome inflamatória multissistêmica (multisystem inflammatory syndrome – MIS-C) associada à Covid-19, o tratamento inicial com imunoglobulina intravenosa (IGIV) e glicocorticoides foi associado com menor risco de disfunção cardiovascular nova ou persistente em comparação ao tratamento com IGIV isolada.

18 Jun, 2021 | 10:40h

Multisystem Inflammatory Syndrome in Children — Initial Therapy and Outcomes – New England Journal of Medicine

Editorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics


Entrevista em áudio | Potenciais tratamentos para crianças com síndrome inflamatória multissistêmica (multisystem inflammatory syndrome – MIS-C) associada à Covid-19.

18 Jun, 2021 | 10:38h

Audio Interview: Covid-19 in Children – New England Journal of Medicine


M-A | Tratamentos agudos para enxaqueca episódica em adultos.

18 Jun, 2021 | 10:28h

Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis – JAMA (gratuito por tempo limitado)

Editorial: Acute Treatment for Migraine: Contemporary Treatments and Future Directions (gratuito por tempo limitado)

 

Comentário no Twitter (fio – clique para saber mais)

 


Estudo randomizado | Tofacitinibe reduziu o risco de morte ou insuficiência respiratória em pacientes hospitalizados com pneumonia por Covid-19.

17 Jun, 2021 | 11:06h

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia – New England Journal of Medicine

Comunicado de imprensa: Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia

 

Comentário no Twitter:

 


[Preprint] Estudo RECOVERY descobre que a combinação de anticorpo monoclonal Regeneron reduz as mortes de pacientes hospitalizados com COVID que não desenvolveram sua própria resposta imunológica.

17 Jun, 2021 | 11:04h

Comunicado de imprensa: RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

Estudo original (preprint): Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv

Comentários: Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients – Science E Antibody combo cuts COVID deaths by 20% in very ill seronegative patients – CIDRAP E Regeneron antibody saves lives in some hospitalized Covid patients, study finds – STAT E Expert reaction to press release from the RECOVERY trial reporting that Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response – Science Media Centre

 

Comentário no Twitter

 


[Comunicado de imprensa – Ainda não publicado] CureVac falha como vacina contra COVID-19 em estudo, com 47% de eficácia.

17 Jun, 2021 | 11:01h

CureVac Fails in Pivotal COVID-19 Vaccine Trial With 47% Efficacy – AP / Reuters

Ver também: CureVac’s COVID-19 shot just failed in a large trial, a major setback for the Gates-backed biotech – Insider

Comunicado de imprensa: CureVac provides update on phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV

 

Comentário no Twitter (fio – clique para saber mais)

 


Série de casos | 7 casos de miocardite após vacinação baseada em mRNA contra COVID-19.

17 Jun, 2021 | 11:00h

Myocarditis after BNT162b2 and mRNA-1273 Vaccination – Circulation

Comentário: Study details the treatment of COVID-19 vaccine-associated myocarditis-like illness in 7 patients – News Medical

Relacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.


Série de casos | Achados clínicos e de ressonância magnética em 4 casos de miocardite após vacinação baseada em mRNA contra COVID-19.

17 Jun, 2021 | 10:58h

Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings – JACC: Cardiovascular Imaging

Comentário: Possible Association Between COVID-19 Vaccine and Myocarditis – American College of Cardiology

Relacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.


Série de casos | Miocardite sintomática aguda em 7 adolescentes após vacinação baseada em mRNA contra COVID-19.

17 Jun, 2021 | 10:57h

Symptomatic Acute Myocarditis in Seven Adolescents Following Pfizer-BioNTech COVID-19 Vaccination – Pediatrics

Relacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.


Revisão sistemática | Segurança e eficácia da metformina em pacientes com função renal reduzida – Segurança e benefício em taxas de filtração glomerular estimada (estimated glomerular filtration rate – eGFR) de 45 mL/min/1,73 m2 ou mais; possivelmente prejudicial em eGFR abaixo de 30 mL/min/1,73 m2.

17 Jun, 2021 | 10:54h

Safety and effectiveness of metformin in patients with reduced renal function: A systematic review – Diabetes, Obesity and Metabolism

 

Comentário no Twitter

 


Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.